Aktienanalyse zu LeMaitre Vascular Inc (LMAT)LMATLeMaitre Vascular Inc

LeMaitre Vascular, Inc. is a provider of devices, implants, and services for the treatment of peripheral vascular disease. It develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser degree, other specialties, such as cardiac surgeons, general surgeons, and neurosurgeons. Its portfolio of product lines is used to treat vascular disease, which are used in open vascular surgery and dialysis access. It offers human vascular and cardiac tissue cryopreservation services. Its principal product lines include anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy and occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. Its principal biologic offerings include vascular and cardiac patches as well as vascular and dialysis grafts. Its product offerings are sold globally in the United States, Europe, Canada and Asia Pacific. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

LeMaitre Vascular Inc is currently a hold. The stock is priced at $84.45, with a forward P/E ratio of 25.58, which suggests it may be overvalued compared to its recent performance. The RSI is at 62.78, indicating it is nearing overbought territory. While the company has shown strong sales growth, with a 34% increase in Artegraft sales, the recent downward revision of revenue guidance to $276.3 million raises concerns about future growth. Additionally, hedge funds have increased selling activity by 398.42%, which may signal caution among institutional investors. Therefore, while there are positive aspects, the risks associated with valuation and insider selling suggest a hold position for now.

8 analysts cover LMAT: 2 rate it Buy, 6 Hold and 0 Sell. The average price target is 105.20.